PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
35.98
-0.36 (-0.99%)
At close: 4:00PM EDT

36.03 +0.05 (0.14%)
After hours: 7:54PM EDT

Stock chart is not supported by your current browser
Previous Close36.34
Open36.35
Bid0.00 x 0
Ask0.00 x 0
Day's Range35.88 - 36.48
52 Week Range29.83 - 36.60
Volume13,581,579
Avg. Volume17,157,668
Market Cap213.99B
Beta1.09
PE Ratio (TTM)26.32
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.28 (3.52%)
Ex-Dividend Date2017-11-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Pres Trump believes he has the cure for Obamacare
    Yahoo Finance Video4 days ago

    Pres Trump believes he has the cure for Obamacare

    President Trump's healthcare bill may have died in Congress, but that's not stopping him from making changes to Obamacare. Later today, the president is expected to sign an executive order that would let Americans buy insurance across state lines. Yahoo Finance’s Alexis Christoforous and Editor-in-Chief Andy Serwer figure out if the the president’s move will help lower premiums.

  • Pharma Industry Outlook - October 2017
    Zacks6 hours ago

    Pharma Industry Outlook - October 2017

    Pharma Industry Outlook - October 2017

  • Investopedia8 hours ago

    How Stock Investors Can Profit Big From Spinoffs

    Spinning Rich Profits: Spinoffs as a group have posted total returns of nearly 300% over 10 years

  • Forbes11 hours ago

    The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad

    The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.

  • The Wall Street Journal15 hours ago

    [$$] Drugstore Favorites May Be Catching the Common Consumer Cold

    Customers may be starting to shop for over-the-counter drugs in the same way they shop for groceries—with a keener eye for cost and content—and this could be painful for consumer-health companies.

  • TheStreet.comyesterday

    Pfizer Consumer Unit Worth as Much as $14 Billion

    A deal would give the company capital to do more deals but the decision also keeps the company's recently scratched plans to split into two separate companies alive. The division itself had about $3.4 ...

  • Motley Fool3 days ago

    Earnings Season Preview: 2 Things to Watch For in Healthcare

    J&J is the lead-off hitter, and its Remicade results will tell us a lot. So will the biosimilar numbers from Pfizer.

  • Motley Fool3 days ago

    Pfizer Says It's Pondering a Big Sale

    The pharmaceutical major announced it's thinking about finding a buyer for its consumer healthcare unit.

  • 5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings
    Zacks3 days ago

    5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings

    The pharma/biotech sector has a number of things going in its favor.

  • Spin-Off ETF: Can the Outperformance Continue?
    Zacks3 days ago

    Spin-Off ETF: Can the Outperformance Continue?

    Spin-off activities picked up pace in the United States.

  • Market Realist3 days ago

    Behind Eli Lilly’s October Analyst Recommendations

    So far in October, of the 22 analysts covering Eli Lilly (LLY), four have suggested a “strong buy,” while ten analysts have suggested a “buy.”

  • Barrons.com3 days ago

    Pharma Sales Could Be Chilled by Hurricane Damage

    Pharmaceutical third-quarter earnings are nearly upon us, and Guggenheim's Tony Butler and Allen Cha provide their thoughts on the upcoming results. Butler and Cha write that the hurricanes are a factor ...

  • Barrons.com4 days ago

    Pfizer: Could a Big Merger Move the Needle?

    T here’s been speculation about whether or not Pfizer (PFE) is planning to make a large acquisition, and Guggenheim’s Tony Butler takes on the question, writing that a smart deal could expand the pharma giant’s multiple. Butler notes that Pfizer’s management has stated that it’s aware of the need to create shareholder value, and he believes that the outcome hinges on a number of factors, including any potential tax reform/cash repatriation holiday, as well as clinical trial results. At the moment, Pfizer has a joint venture with Merck (MRK) to develop Bavencio, a PD-L1 antibody, but Butler wonders if it might be willing to step back if the data isn’t supportive, and if it might be willing to acquire a company with a different, PD-1 antibody—again if the data bears it out.

  • Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback
    Zacks4 days ago

    Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback

    Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.

  • Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
    InvestorPlace4 days ago

    Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy

    Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.

  • Motley Fool4 days ago

    2 Reasons Pfizer Is on Our Minds Today

    First, it raised some spinoff speculation. Second, it's in an intriguing tussle with J&J that could affect the biosimilars market for everyone.

  • Barrons.com4 days ago

    [$$] Pfizer Seen Mulling Options

    Credit Suisse We are not surprised by Pfizer’s announcement [Tuesday] morning that they are exploring strategic options for their Consumer Healthcare business. Based on our recent conversations with the company, it had become clear to us that Pfizer (PFE) management does not see this business as part of their long-term innovative core. After speaking with the company again today and based on their previous transactions, we assume Pfizer will take their usual time and care in exploring all options.

  • Motley Fool5 days ago

    Is Pfizer the Best Dividend Stock in Healthcare?

    A push into cancer drugs and biosimilars could make this a good time to buy Pfizer’s shares.

  • American City Business Journals5 days ago

    Pfizer considers selling unit that includes Advil, ChapStick

    Pharmaceutical giant Pfizer Inc. is reviewing a sale process for its consumer healthcare business. A spin-off is also possible, Pfizer (PFE) noted. The segment is touted as one of the largest over-the-counter health care products businesses in the world, consisting of well-known products that include dietary supplement Emergen-C, Advil, Thermacare, Robitussin and ChapStick.

  • Three blue-chip US companies are on the verge of breaking apart, prodded by short-term investors
    Quartz5 days ago

    Three blue-chip US companies are on the verge of breaking apart, prodded by short-term investors

    The CEOs of Procter & Gamble, Honeywell, and Pfizer are all under pressure to split up their companies. The reasons are different but root cause is the same: the rapacious hunger of short-term investors. Procter & Gamble, seller of toothpaste and toilet paper, drew headlines this week by narrowly winning a proxy battle with Nelson…

  • Barrons.com5 days ago

    Pfizer: Who Will Pay $14B for Advil?

    Just imagine if Pfizer (PFE) is able to sell its consumer products business? In a note published today, Credit Suisse’s Vamil Divan believes that either a sale or a spinoff is a sure thing on the heels of the pharmaceutical giant’s announcement Tuesday that it was weighing options for the business. It was barely a year ago that Pfizer abandoned the long-debated notion of breaking itself up into two separate companies.

  • Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit
    Zacks5 days ago

    Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit

    Pfizer (PFE) is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin-off, sale or other transaction.

  • 3 Reasons Why Pfizer Investors Will Win With a Consumer Business Sale or Spinoff
    Motley Fool6 days ago

    3 Reasons Why Pfizer Investors Will Win With a Consumer Business Sale or Spinoff

    Could good news be on the way for Pfizer shareholders?

  • $100 Billion Question: Will Trump Let Alphabet, Pfizer Keep Tax Havens?
    Investor's Business Daily6 days ago

    $100 Billion Question: Will Trump Let Alphabet, Pfizer Keep Tax Havens?

    Tax reform may not be as great as expected for companies with low international tax rates.

  • The Wall Street Journal6 days ago

    [$$] The Reason Investors Love Spinoffs: Juicier Returns

    Pfizer and Honeywell announced plans to hive off major business units, a reminder that spinoffs remain popular with executives as well as investors, who appreciate their long history of outperforming the ...